CONTRACT NUMBER DAMD17-97-C-7052

TITLE: Analytical and Characterization Studies of Organic Chemicals, Drugs and Drug Formulation

PRINCIPAL INVESTIGATOR: Peter Lim, Ph.D.
Lori Olson, M.S.

CONTRACTING ORGANIZATION: SRI International
Menlo Park, California 94025-3493

REPORT DATE: July 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**REPORT DOCUMENTATION PAGE**

<table>
<thead>
<tr>
<th>1. AGENCY USE ONLY (Leave blank)</th>
<th>2. REPORT DATE</th>
<th>3. REPORT TYPE AND DATES COVERED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>July 1998</td>
<td>Annual (1 Jul 97 - 30 Jun 98)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. TITLE AND SUBTITLE</th>
<th>5. FUNDING NUMBERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analytical and Characterization Studies of Organic Chemicals, Drugs and Drug Formulation</td>
<td>DAMD17-97-C-7052</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. AUTHOR(S)</th>
<th>8. PERFORMING ORGANIZATION REPORT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lim, Ph.D. and Lori Olson, M.S.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</th>
<th>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRI International</td>
<td>U.S. Army Medical Research and Materiel Command</td>
</tr>
<tr>
<td>Menlo Park, California 94025-3493</td>
<td>Fort Detrick, Maryland 21702-5012</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11. SUPPLEMENTARY NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12a. DISTRIBUTION / AVAILABILITY STATEMENT</th>
<th>12b. DISTRIBUTION CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved for public release; distribution unlimited</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13. ABSTRACT (Maximum 200 words)</th>
</tr>
</thead>
<tbody>
<tr>
<td>During the annual contract period, 1 July 1997 to 30 June 1998, 9 samples of bulk drugs and dosage formulations were analyzed for identity, purity or potency; 3 special plasma extraction methods were developed, and 13 samples were studied for stability and solubility. Six chiral separation methods were developed and validated. Over two hundred PDF documents were prepared for the WRAIR's online chemical database. One manuscript was submitted for publication.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. SUBJECT TERMS</th>
<th>15. NUMBER OF PAGES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>16. PRICE CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. SECURITY CLASSIFICATION OF REPORT</th>
<th>18. SECURITY CLASSIFICATION OF THIS PAGE</th>
<th>19. SECURITY CLASSIFICATION OF ABSTRACT</th>
<th>20. LIMITATION OF ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unclassified</td>
<td>Unclassified</td>
<td>Unclassified</td>
<td>Unlimited</td>
</tr>
</tbody>
</table>

NSN 7540-01-280-5500

Form Approved
OMB No. 0704-0188

USAPPC V1.00
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the “Guide for the Care and Use of Laboratory Animals,” prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

______

PI - Signature       June 1998
Table of Contents

FOREWORD ................................................................................................................. 3

INTRODUCTION ........................................................................................................ 5

ANNUAL REPORT (1997-1998) ................................................................................ 6

SAMPLE ANALYSES .................................................................................................. 6

SPECIAL METHOD DEVELOPMENTS ...................................................................... 6

STABILITY AND SOLUBILITY STUDIES ................................................................ 7

CHIRAL SEPARATIONS AND METHOD VALIDATIONS ........................................... 8

PORTABLE DOCUMENT FORMAT (PDF) REPORTS .............................................. 8

PUBLICATIONS ........................................................................................................ 9

PERSONNEL .............................................................................................................. 9

SUMMARY/CONCLUSION ......................................................................................... 10
INTRODUCTION

This annual report for Contract DAMD17-97-C-7052 covers the period from 1 July 1997 to 30 June 1998. The report consists of a listing of the compounds/samples analyzed and a summary of the number of the types of studies performed. The report also includes a listing of personnel receiving pay from this effort and a bibliography of all publications and meeting abstracts that resulted from this contract.

This contract is concerned with the analytical, characterization, and stability studies of chemicals, drugs, and drug formulations. The work is monitored by Mr. William Y. Ellis, the Contracting Officer Representative (COR), Chief, Chemical Handling and Data Analysis Branch, Division of Experimental Therapeutics, Walter Reed Army Institute of Research (WRAIR).

The overall objective of this project, a continuation of one that started in 1966, is the operation of an analytical laboratory to determine the identity, purity, strength, quality, physical and chemical properties, and stability of bulk pharmaceutical substances and formulated drug products of interest to the USAMRMC Drug Development Program for parasitic and infectious diseases, chemical and biological defense, anti-viral studies, etc. Specific objectives are to: design, develop, validate, and execute methods to determine the following characteristics of candidate bulk pharmaceutical substances and formulated drugs:

- Identity, purity, and strength.
- Stability.
- Other physical and chemical characteristics, including weight variation, content uniformity, and other such compendial requirements.
- Qualitative and quantitative identity of impurities.
- Special projects not covered by the above headings.
ANNUAL REPORT (1997-1998)

Sample Analyses

During the contract period, 1 July 1997 to 30 June 1998, analyses of the following samples were completed and the reports sent to the COR.

1. WR6026; BN42485, 6-methoxy-8-(6-diethylaminohexylamino) lepidine dihydrochloride, 5-mg capsule HPLC assay, Report No. 941.

2. WR6026; BN42494, 6-methoxy-8-(6-diethylaminohexylamino) lepidine dihydrochloride, 15-mg capsule HPLC assay, Report No. 942.

3. WR6026; BN42501, 6-methoxy-8-(6-diethylaminohexylamino) lepidine dihydrochloride, 30-mg capsule HPLC assay, Report No. 943.

4. WR238605; BM08200, N^4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoro-methyl)phenoxy)-8-quinoliny1)-1,4-pentanediamine succinate, 5-mg capsule assay, Report No. 944.

5. WR238605; BM08219, N^4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoro-methyl)phenoxy)-8-quinoliny1)-1,4-pentanediamine succinate, 15-mg capsule assay, Report No. 945.

6. WR243251 and WR243246, qualitative HPLC method to separate WR243251 from WR243246, Report No. 958.

7. WR279396; BN85622, paromomycin and gentamicin in cream formulation; assay for paromomycin, Report No. 938.

8. WR279396; BN85622, paromomycin and gentamicin in cream formulation, assay for gentamicin, Report No. 939.

9. WR279396; BN85622, placebo cream formulation, assay for presence of paromomycin or gentamicin, Report No. 940.

Special Method Developments

Drug blood plasma extraction studies were performed and the following HPLC methods were developed:

1. WR2976; AW23860, extraction and quantitation in rabbit plasma, Report No. 961.
2. WR142490; BE10189, enantioselective HPLC analysis of WR142490 in rabbit plasma, Report No. 960.

3. WR171669; BL56676 and WR178460; BN78716, extraction of WR171669, (±)-Halofantrine and WR178460, (±)-Desbutylhalofantrine from rabbit plasma; subsequent quantitation by chiral HPLC, Report No. 962.

**Stability and Solubility Studies**

Stability and solubility studies on the following samples have been completed and the reports submitted to the COR.

1. WR171669AS; BL56676, 1,3-dichloro-6-trifluoromethyl-9-[1-hydroxy-3-(di-n-butylamino)propyl]phenanthrene hydrochloride, 9-yr shelf-life stability study, Report No. 957.

2. WR178460; BN78716, lot JEF-28030-36, desbutylhalofantrine hydrochloride, room-temp, 1.5-yr shelf-life stability, Report No. 966.

3. WR178460; BN78716, desbutylhalofantrine, 1-yr room-temperature shelf-life stability study, Report No. 952.

4. WR178460; BN78716, desbutylhalofantrine, 35 °C 3-mo accelerated stability study, Report No. 946.

5. WR178460; BN78716, desbutylhalofantrine, 50 °C 3-mo accelerated stability study, Report No. 947.

6. WR178460; BN78716, desbutylhalofantrine, 35 °C 9-mo accelerated stability study, Report No. 963.

7. WR178460; BN78716, desbutylhalofantrine, 50 °C 9-mo accelerated stability study, Report No. 964.

8. WR242511AE; BM05816, 8-[(4-amino-1-methylbutyl)amino]-5-(1-hexyloxy)-6-methoxy-4-methylquinoline DL-tartrate, 7-yr shelf-life stability study, Report No. 956.

9. WR243251AB; BJ45753, 7-Chloro-3-(2"",4""-dichlorophenyl)-1-[[3'- (dimethylamino)propyl]iminoo]-1,2,3,4-tetrahydro-9-(10H)-acridone, 9-mo shelf-life stability study, Report No. 953.

10. WR250547AB; BL34170, 9-mo shelf-life stability study, Report No. 954.

11. WR250548AB; BL29759, 9-mo shelf-life stability study, Report No. 955.

12. WR255663AK; BM04131, 8-yr shelf-life, Report No. 965.

Chiral Separations and Method Validations

Chiral separations on the following samples have been completed and the reports have been sent to the project COR.

1. WR178460; BN78716, desbutylhalofantrine hydrochloride, chiral HPLC assay validation, Report No. 918.

2. WR242511; 8-[(4-amino-1-methylbutyl)amino]-5-(1-hexyloxy)-6-methoxy-4-methylquinoline DL-tartrate, a method development and validation of a chiral HPLC method for racemic bulk, Report No. 948.

3. WR280510; BN65139, R(-)-8-[(4-Amino-1-methylbutyl)amino]-5-(1-hexyloxy)-6-methoxy-4-methylquinoline DL-Tartrate, validation of a chiral HPLC method, Report No. 950.

4. WR280511; BN65148, S(+-)8-[(4-Amino-1-methylbutyl)amino]-5-(1-hexyloxy)-6-methoxy-4-methylquinoline DL-Tartrate, validation of a chiral HPLC method, Report No. 951.

5. WR280691; BN79803, (-) desbutylhalofantrine hydrochloride, chiral HPLC validation, Report No. 936.

6. WR280823; BN78716, (+) desbutylhalofantrine hydrochloride, chiral HPLC validation, Report No. 937.

Portable Document Format (PDF) Reports

A large number (205) of completed technical reports in electronic portable document format (PDF) were uploaded to WRAIR's ETIMAGE server. These PDF documents were:
Publications

The following manuscript has been submitted for publication:

1. “A Chiral HPLC Analysis of a Substituted Aminoquinoline Analog, WR242511”, by Lori L. Olson, Tina Nguyen, John Pick, and William Y. Ellis, was submitted for potential publication.

Abstract: This paper reports, for the first time, a simple and sensitive chiral HPLC-based method for the enantiomeric resolution and quantitation of a racemic aminoquinoline analog, WR242511, a drug of interest in the treatment of Malaria, pneumocystis pneumonia and cyanide prophylaxis. Baseline resolution of the racemate into its enantiomers was achieved by utilizing a polysaccharide-type HPLC column. Validation data for precision, linearity, accuracy, lower limit of detection and stability of each enantiomer and the racemate are presented. This method may be applicable to separate other racemic aminoquinoline analogs, and with modification, could be considered for scaled up production of the enantiomers.

Personnel

A listing of personnel who received major contract support is as follows:

Peter Lim, P.I.
Lori Olson, Assistant P.I.
John Pick, Chemist
Tina Nguyen, Chemist
Summary/Conclusion

During the annual contract period, 9 samples of bulk drugs and dosage formulations were analyzed for identity, purity or potency, 3 special plasma extraction methods were developed, and 13 samples were studied for stability and solubility. Six chiral separation methods were developed and validated. Over two hundred PDF documents were prepared for the WRAIR's online chemical database. One manuscript was submitted for publication.

Respectfully submitted,

Peter Lim
Principal Investigator
Phone: (650) 859-3029
Fax: (650) 859-4321

Lori L. Olson
Assistant Principal Investigator
Phone: (650) 859-2765
Fax: (650) 859-4321
E-Mail: hobbit@mddlearth.sri.com
holdhobbit@pearl.sri.com